Source: Trial Site News

Treatments for early-onset COVID-19 are in the works at the University of Minnesota as they conduct the nation’s first randomized trial of Ivermectin. Being studied as an outpatient treatment to prevent coronavirus infection, the anti-parasitic has immense potential and is in use in various countries all over the world. 

There’s building tension as on the one hand dozens of completed randomized trials’ evidence are all but ignored but major institutions such as the U.S. Food and Drug Administration (FDA) yet on the other hand COVID-19 patient families increasingly take their demands to courts as hospital physicians refuse to treat COVID-19 patients with ivermectin.

Leading the national trial is Dr. Carolyn Bramante, a U internal medicine specialist. Emphasizing the importance of this trial, she says, “Not everybody has access to the vaccine, whereas these medications are existing generics, already FDA-approved, that are available in most pharmacies around the world.” Dr. Bramante continued, “If we find evidence of benefit, [the drugs] could be used immediately anywhere.”

Study Details

U research already has shown possible benefits of metformin, usually used to manage diabetes, in reducing COVID-19 illness and death in women. But now researchers will compare its effectiveness against ivermectin as well as fluvoxamine, an antidepressant. The U started recruiting up to 1,100 patients 30 or older last week to receive one of the drugs, alone or in combination with metformin, or a non-medicating placebo for comparison.

Effectiveness will primarily be measured by whether patients suffer hypoxia — severe oxygen deficiency.

Bramante said ivermectin has anti-inflammatory benefits that need closer study to see if it inhibits the overreaction to infection by the immune system that can cause severe COVID-19 symptoms.

Funding and Challenges

The Rainwater Charitable Foundation that provided $1 million for the U trial had an interest in studying ivermectin and sponsored a similar trial in Brazil.

The U trial is challenging because clinicians suspect that the drugs work best when provided as early as possible. Recruits must have had positive test results within three days, and the goal is to ship overnight study medications to them so they will start taking them within seven days.

Lead Research/Investigator

Carolyn Bramante, MD, MPH, is an internist, pediatrician, and obesity medicine doctor who cares for children at the University of Minnesota Health Masonic Children’s Hospital Pediatric Specialty Care Discovery Clinic.

Related: Dr Tess Lawrie’s Powerful Closing Address at the International Ivermectin for Covid Conference​

Interview with Zimbabwe’s Dr. Jackie Stone: COVID-19 Infection & DEATH RATES PLUMMET Post MCAZ green light for Ivermectin Use

The International Ivermectin for Covid Conference​: Recent findings from the Israeli trial of ivermectin versus placebo

Brazil: Minister of Health considers hydroxychloroquine and ivermectin in drug protocol against Covid-19

Zimbabwe Physician Reports Ivermectin Correlated with Dramatic Decrease in Cases & Deaths

Dr Pierre Kory Talks Ivermectin Success – Benefits Ricochet Around the World

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Stark madness to ban ivermectin

Buried in the note is the real reason for making ivermectin inaccessible – the fear that persons taking it ‘may elect not to be vaccinated as part of the national Covid-19 vaccination program’. This is outrageous. When someone is infected with Covid, it is too late to bother with vaccination. They need early treatment. To deny it to coerce them into accepting a vaccine, one of whose side-effects is death, is immoral.

Read More »

Australia’s TGA Bans GPs from Prescribing Ivermectin

Australia’s medicine and therapeutic regulatory, the Therapeutic Good Administration (TGA) recently took the gloves off with Ivermectin, the economical anti-parasitic drug associated with at least 63 completed clinical trials involving SARS-CoV-2, the virus behind COVID-19. Now TGA formally places a national prohibition on off-label prescribing of ivermectin to all general practitioners. A comparable move as to what TGA did with hydroxychloroquine in 2020. Clearly further evidence of tightening encroachment of the critically important doctor-patient treatment relationship allowing consent to medical treatment using off-label medications. Of course, this isn’t occurring in a vacuum—it’s part of an unfolding, integrated and what have the signs of a coordinated and orchestrated government action to stop any and all treatments other than those the government declares acceptable.

Read More »